Rxrx stock forecast.

With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations. Recursion Pharmaceuticals, Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales ... Now's a great time to invest in biotechs that have AI as a tailwind. Ginkgo Bioworks uses AI to run bioengineering projects for other biotechs. Recursion Pharmaceuticals uses AI to find good leads ...

Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

(See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy , a newly launched tool that unites all of TipRanks’ equity insights.On May 8, Recursion Pharmaceuticals (RXRX 7.88%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock.

Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.Gas prices are at a record high, and experts are forecasting that prices could go higher this summer — perhaps $5 or even over $6 a gallon. By clicking "TRY IT", I agree to receive newsletters and promotions from Money and its partners. I a...Dec 1, 2023 · Company Summary. Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data ... All of that said, let's take a look at the consensus forecast for Wood's newest addition to her flagship fund - an unprofitable biotech stock under $10. About Recursion Pharmaceuticals Headquartered in Salt Lake City, Recursion Pharmaceuticals RXRX is a clinical-stage biotechnology company that is pioneering the use of machine learning and …

The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months.

Gas prices are at a record high, and experts are forecasting that prices could go higher this summer — perhaps $5 or even over $6 a gallon. By clicking "TRY IT", I agree to receive newsletters and promotions from Money and its partners. I a...

According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an increase of 120.26%. The lowest target is $8.00 and the highest is $33. On average, analysts rate RXRX stock stock as a buy.Analyst Price Forecast Suggests 117.07% Upside As of July 6, 2023, the average one-year price target for Recursion Pharmaceuticals Inc - is 14.72. The forecasts range from a low of 8.08 to a high ...Get free stock tools, free stock ratings, free stock charts and calculate the value of stocks to buyRecursion Pharmaceuticals Stock Prediction. BSX. 63Sep 22, 2023 · According to data from CNN Money, the company had 7 analysts offering 12-month price forecasts. The median target price was $14.00, with a high estimate of $35.00 and a low estimate of $9.00. The consensus among the 7 polled investment analysts was to hold the stock of Recursion Pharmaceuticals Inc. This rating had remained steady since ...

Analyst Future Growth Forecasts. Earnings vs Savings Rate: RXRX is forecast to remain unprofitable over the next 3 years. Earnings vs Market: RXRX is …Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ...Based on short-term price targets offered by seven analysts, the average price target for Recursion Pharmaceuticals comes to $15.29. The forecasts range from a low of $9.00 to a high of $33.00 ...Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.If you bought Keurig K-Cup coffee pods at any point between June 2016 and August 2022, you might be entitled to some cash from a court settlement.In the last three months, insiders have sold 333,493 shares of company stock worth $2,375,196. 19.96% of the stock is currently owned by insiders. Wall Street Analysts Forecast GrowthOn Monday, RXRX stock opened at $9.12. The company’s one-year low is at $4.54 while its one-year high stands at $16.75 – indicating potential volatility in its trading range in the past year. Recursion Pharmaceuticals has a market capitalization value of $1.97 billion along with a PE ratio of -6.61 and a beta coefficient of -0.05 ...

Analyst Price Forecast Suggests 117.07% Upside As of July 6, 2023, the average one-year price target for Recursion Pharmaceuticals Inc - is 14.72. The forecasts range from a low of 8.08 to a high ...

What is Recursion Pharmaceuticals, Inc. (RXRX) stock EPS forecast? Recursion Pharmaceuticals, Inc. missed analysts’ expectations during the last earnings period by 13.16% . Recursion Pharmaceuticals, Inc. reported earnings of -$ 0.43 per share on Nov 9, 2023, while the forecasted EPS was -$ 0.38.4.31%. €8.59M. RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 26th, 2024 based off prior year's report dates. Read More.Recursion Pharmaceuticals Inc Cl A stocks price quote with latest real-time prices, charts, financials, ... RXRX Related stocks. Symbol 3M %Chg ; RXRX -18.97% : Recursion Pharmaceuticals Inc Cl A: ZTS -6.96% : Zoetis Inc Cl A: TAK ... Cash Markets Overview Corn Indexes Soybean Indexes Yield Forecast Indexes.Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Recursion Pharmaceuticals, Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales ... Analysts have provided the following ratings for Recursion Pharmaceuticals (NASDAQ:RXRX) within the last quarter: These 7 analysts have an average price target of $18.14 versus the current price ...

2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ...

Get free stock tools, free stock ratings, free stock charts and calculate the value of stocks to buy

If you bought Keurig K-Cup coffee pods at any point between June 2016 and August 2022, you might be entitled to some cash from a court settlement.RXRX : RECURSION PHARMACEUTICALS-A stock forecast by Wall Street Analysts. The average RECURSION PHARMACEUTICALS-A stock forecast from last 6 month is $16.9, and this show a 3.7% increase in average from the prior price target of the each prediction.View the latest Recursion Pharmaceuticals Inc. (RXRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.The exchange reported a loss of $2.43 per share, compared to forecasts of a $2.52 loss per share, according to the FactSet consensus. Revenue plummeted 75% to $629.1 million, but still beat ...What this means: Recursion Pharmaceuticals Inc Cl (RXRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.Analyst projections state that RXRX is forecast to be at a low of $9.00 and a high of $35.00. In order for the stock price to hit the forecast high, the stock would need to plunge -532.91% from its current level, while the stock would need to crash -62.75% from its current level to reach the projected low.Dec 1, 2023 · Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 26th, 2024 based off prior year's report dates. Read More. Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.gguy44. Recursion Pharmaceuticals ( NASDAQ: RXRX) is up 17% on Wednesday in much higher than usual volume as it may be in a short squeeze situation. As of 1215p ET, volume was ~16.6M shares ...What is Recursion Pharmaceuticals, Inc. (RXRX) stock EPS forecast? Recursion Pharmaceuticals, Inc. missed analysts’ expectations during the last earnings period by 13.16% . Recursion Pharmaceuticals, Inc. reported earnings of -$ 0.43 per share on Nov 9, 2023, while the forecasted EPS was -$ 0.38.2 days ago · The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by JP Morgan on Monday, November 13, 2023. The analyst firm set a price target for 10.00 expecting RXRX to rise ...

Find the latest Vacasa, Inc. (VCSA) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid Term ...Recursion's stock soared 80% following the announcement. Shares of Nvidia, which have helped fuel stock market gains this year amid hopes about its AI computing chips , rose more than 2%.That’s as shares of Recursion Pharmaceuticals RXRX are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session. Butterfly with parabolic D leg action. This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention.Recursion Pharmaceuticals (RXRX) stock price prediction is 10.137756245264 USD. The Recursion Pharmaceuticals stock forecast is 10.137756245264 USD for 2024 December 02, Monday; and 517.401 USD for 2028 December 02, Saturday with technical analysis.Instagram:https://instagram. what is the best jewelry insurance company401k contribution limits 2024 over 50how much is 1 gold bareasiest financial designations to get Great weather can motivate you to get out of the house, while inclement weather can make you feel lethargic. When the weather’s great we want to be outside enjoying it. For the best regional weather forecasts check out AccuWeather. no load index fundsunstoppable domains vs ens Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ... best performing gold mutual funds Analysts have provided the following ratings for Recursion Pharmaceuticals (NASDAQ:RXRX) within the last quarter: These 7 analysts have an average price target of $18.14 versus the current price ...The 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating Based on 7 analysts giving stock ratings to RXRX in the past 3 months.Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.